TD Cowen Maintains Buy Rating for Geron (GERN) While Trimming PT to $3 Ahead of Q4 Results

Group 1 - Geron Corporation (NASDAQ:GERN) is recognized as a fast-growing penny stock, with analysts maintaining a Buy rating despite a price target reduction from $4 to $3 by TD Cowen [1][3] - In Q3 2025, Geron added 150 new ordering accounts, marking a 15% sequential increase, and initiated its first shipment of RYTELO to Germany under an early access program [2] - The clinical pipeline is progressing well, with the Phase 3 trial for relapsed/refractory myelofibrosis fully enrolled and an interim analysis expected in the second half of 2026 [2] Group 2 - RYTELO demand experienced a 3% decline compared to the previous quarter, attributed to a balance between new patient starts and discontinuations in later-line therapies [3] - To counteract these challenges, Geron has implemented a restructuring plan and provided financial guidance for 2026, projecting RYTELO revenue between $220 million and $240 million, with a focus on achieving profitability and enhancing its commercial presence [3]